Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

This study has been completed.
Sponsor:
Collaborator:
Onxeo
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc
ClinicalTrials.gov Identifier:
NCT00865969
First received: March 19, 2009
Last updated: December 4, 2014
Last verified: December 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2014
  Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)